Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio. Read why I ...

Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...

While you can’t control death, you can control how much you pay in taxes. That’s particularly true for dividend investors. After all, if you don’t manage your tax exposure, the income you ...

Buy GILD near 85.09 target n/a stop loss @ 84.84. Details The technical summary data tells us to buy GILD near 85.09, but there is no current upside target from the summary table. In this case we ...

Xavier Lorenzo / Investopedia Many people invest in dividend-bearing mutual funds to generate additional income. While this can be simple and effective in increasing your regular earnings ...